Andrew Satz on the Talent Finders Podcast

Jun 15, 2020 | Blog, News | 0 comments

Daniel Gigante

EVQLV’s CEO, Andrew Satz, joined Kerrin Black of the Talent Finders Podcast to discuss his entrepreneurial journey, some of the challenges facing AI for drug discovery, his legacy and much more. Give it a listen below.

Timestamps:

Andrew’s entrepreneurial journey – 0:46

Insight into what EVQLV does – 6:05

Lessons learned in Andrew’s career – 14:17

Was this something Andrew always knew he wanted to do? – 20:27

What are some of the challenges facing artificial intelligence in healthcare – 23:28

Discussion on leadership – 30:21

Benefits of AI and the responsibility facing those developing AI – 34:08

Career highlights – 37:19

The future of medicine and telemedicine with respect to AI – 41:05

Effects of AI on privacy – 45:04

advise for entrepreneurs – 49:03

Andrew’s legacy – 55:56

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

NY Bio-Computation Startup EVQLV Closes Financing Round

NEW YORK, February 8, 2021 -- EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, today announced the closing of a funding round that will be used to advance the company’s R&D efforts, boost development...

EVQLV Welcomes Operations & Finance Lead Alexander Sonneborn

NEW YORK, February 1, 2021 -- EVQLV is pleased to announce that Alexander Sonneborn has joined EVQLV to oversee company operations and finances. After an early career in the life sciences, Alexander transitioned to entrepreneurial activities in technology-based...

EVQLV Submits 1 Million Ab Initio Derived Sequences for Validation

NEW YORK, January 12, 2021 - EVQLV has submitted one million AI-generated sequences for independent laboratory validation in fulfillment of the second phase of a project with its collaborator. The first phase of the project consisted of 100 antibody sequences based...

Fully Automated Rabbit Humanization Project Initiated w/ U Buffalo

NEW YORK, December 16, 2020 -- EVQLV is eagerly anticipating the results from the second phase of their University at Buffalo rabbit-humanization collaboration. Starting with rabbit monoclonal antibodies, EVQLV is attempting to validate its fully-automated...

EVQLV Accepted to Prestigious Techstars Boston Accelerator

NEW YORK, November 18, 2020 -- EVQLV, a New York company that uses AI to accelerate the development of antibodies, will be one of 10 startups in the new class of the Techstars Boston program. This year’s program will be 100% virtual and, for the first time, will...

Pin It on Pinterest